Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
381712
Created by
admin on Wed Apr 02 17:09:32 GMT 2025 , Edited by admin on Wed Apr 02 17:09:32 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
16143342
Created by
admin on Wed Apr 02 17:09:32 GMT 2025 , Edited by admin on Wed Apr 02 17:09:32 GMT 2025
|
PRIMARY | |||
|
AEM-28
Created by
admin on Wed Apr 02 17:09:32 GMT 2025 , Edited by admin on Wed Apr 02 17:09:32 GMT 2025
|
PRIMARY | ClinicalTrials.gov Identifier: NCT02100839; The purpose of the first part of this study is to determine the safety and tolerability of a single dose of AEM-28, an apolipoprotein E mimetic, in subjects with high total cholesterol who are otherwise healthy subjects. The pharmacokinetics and pharmacodynamics of AEM-28 will also be evaluated. The second part of this study will be a multiple ascending dose evaluation of AEM-28 in patients with refractory hypercholesterolemia.AEM-28 has demonstrated significant lipid lowering activity and positive effects on the artery wall. AEM-28 is being developed for the treatment of homozygous familial hypercholesterolemia. | ||
|
V9526P2UXZ
Created by
admin on Wed Apr 02 17:09:32 GMT 2025 , Edited by admin on Wed Apr 02 17:09:32 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
